Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,371 across all filing types
Latest filing 2026-04-27 Environmental & Social …
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025
Environmental & Social Information Classification · 1% confidence The document is titled “2025 Environmental, Social and Governance Report” and contains detailed chapters on the company’s environmental performance (e.g., greenhouse gas emissions), social initiatives (e.g., community engagement, employment management), and governance structures (e.g., ESG governance, board statements). It is the full ESG report rather than an announcement, regulatory notice, or financial statement. This matches the Environmental & Social Information category.
2026-04-27 English
2025 ANNUAL REPORT
Regulatory Filings
2026-04-27 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change Classification · 1% confidence The document is a statutory “Next Day Disclosure Return” (HKEx Form FF305) reporting changes in issued shares under Listing Rule 13.25A/17.27A (issue of new shares under an RSU scheme). It details the class and number of shares issued, opening/closing balances, and confirmations of compliance. This is not a general annual or financial report but a specific corporate action announcement concerning share capital changes. It therefore falls under Share Issue/Capital Change (SHA).
2026-04-23 English
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement by CStone Pharmaceuticals regarding the completion of a equity placing of 118,000,000 new shares under the company’s general mandate, detailing the placing price, allotment of shares, use of proceeds and changes in shareholding structure. This falls squarely under an announcement of a new share issue / capital change, which corresponds to the Share Issue/Capital Change category (Code: SHA).
2026-04-22 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change Classification · 1% confidence The document is a statutory Next Day Disclosure Return (Form FF305) under Hong Kong Stock Exchange rules, detailing multiple allotments and issuances of new ordinary shares (from employee share option exercises and a placing under a general mandate) and updates in issued share capital. It is not a short announcement of a report nor an earnings release or management commentary, nor a repurchase. It clearly falls under announcements of new share issues and capital structure changes, matching the “Share Issue/Capital Change” category (SHA).
2026-04-22 English
VOLUNTARY ANNOUNCEMENT - ASCO 2026 PREVIEW: CSTONE TO PRESENT UPDATED CLINICAL DATA FOR CS2009 (PD 1/VEGF/CTLA 4 TRISPECIFIC ANTIBODY)
Regulatory Filings Classification · 1% confidence The document is a voluntary press release by CStone Pharmaceuticals announcing upcoming clinical data presentations at the ASCO Annual Meeting 2026. It does not contain financial results, board changes, share transactions, or formal report attachments. It is a general corporate/regulatory announcement that does not fit the specific categories of earnings release, annual/interim reports, M&A, etc. As such, it falls under the fallback category of general regulatory filings (RNS).
2026-04-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.